- Home
- VTVT
as 06-04-2025 10:43am EST
vTv Therapeutics Inc is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. Its product pipeline include TTP399, TTP273, HPP737, HPP593, Azeliragon, HPP971, HPP3033, and TTP-RA.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HIGH POINT |
| Market Cap: | 56.7M | IPO Year: | 2015 |
| Target Price: | $35.50 | AVG Volume (30 days): | 5.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -7.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.12 - $26.99 | Next Earning Date: | 05-15-2025 |
| Revenue: | $17,000 | Revenue Growth: | -98.30% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest vTv Therapeutics Inc. News
VTVT Breaking Stock News: Dive into VTVT Ticker-Specific Updates for Smart Investing
MT Newswires
16 days ago
vTv Therapeutics Names Michael Tung as Finance Chief
GlobeNewswire
16 days ago
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to Insulin
Associated Press Finance
20 days ago
VTv Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
20 days ago
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update
MT Newswires
20 days ago
vTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes
GlobeNewswire
20 days ago
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes
Zacks
2 months ago
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Associated Press Finance
2 months ago
VTv Therapeutics: Q4 Earnings Snapshot
Compare VTVT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTVT vTv Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.